基石药业(02616.HK):与EQRx合作项目提前通过美国许可
基石药业-B(02616.HK)公布就早前与EQRx Inc签订的舒格利单抗及CS1003(抗PD-1单抗)独家许可协议,双方达成的全球战略合作协议已提前得到美国联邦贸易委员会许可,通过美国1976 Hart-Scott-Rodino 反托拉斯改进法(HSR)的等待期。至此,该合作协议的全部条件已具备,交易正式生效。
根据协议条款,基石药业将获得1.5亿美元的首付款,及最高可达11.5亿美元的里程碑付款,以及额外的分级特许权使用费。
EQRx公司将获得舒格利单抗和CS1003在除中国大陆、台湾地区、香港特区和澳门特区(大中华区)以外的全球市场的独家商业化权利。基石药业将保留C S1003在大中华区的开发和商业化权利,并将继续探索其作为单药和联合疗法的骨架产品的发展前景。(wl/t)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.